Influence of a Dopamine Pathway Additive Genetic Efficacy Score on Smoking Cessation: Results from Two Randomized Clinical Trials of Bupropion by David Sean P, Strong David R, Leventhal Adam M, Lancaster Molly A, McGeary John E, Munafò Marcus R, Bergen Andrew W, Swan Gary E, Benowitz Neal L, Tyndale Rachel F, Conti David V, Brown Richard A, Lerman Caryn, Niaura Raymond in Addiction (Abingdon, England) (2013). PubMed

Abstract

To evaluate associations of treatment and an 'additive genetic efficacy score' (AGES) based on dopamine functional polymorphisms with time to first smoking lapse and point prevalence abstinence at end of treatment among participants enrolled in two randomized clinical trials of smoking cessation therapies.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

None.